Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02947945 · ClinicalTrials.gov registry record · Phase 2
Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study
A Phase 2 study, sponsored by National Jewish Health.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT02947945 is a Phase 2 study that is actively recruiting participants, run by National Jewish Health. The registered enrollment target is 10 participants.
The verdict
NCT02947945, a Phase 2 study, is actively recruiting participants, sponsored by National Jewish Health.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
Reslizumab is a type of medicine called a monoclonal antibody that is made in the research clinic; it works by blocking a specific protein in the body called interleukin-5. The study medicine, reslizumab, is not yet approved for doctors to treat patients with EGPA. It is considered an experimental drug in this study.
Interventions
- DRUG Reslizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2017-09-12 |
| Est. Completion | 2018-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02947945
The ClinicalTrials.gov registry entry for NCT02947945 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Jewish Health, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Reslizumab is the first listed.
NCT02947945 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02947945 about?
NCT02947945 is a clinical study titled "Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study". Reslizumab is a type of medicine called a monoclonal antibody that is made in the research clinic; it works by blocking a specific protein in the body called interleukin-5. The study medicine, reslizumab, is not yet approved for doctors to treat patients with EGPA. It is considered an experimental d...
What is the current status of trial NCT02947945?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2017-09-12. Estimated completion is 2018-12.
What interventions are being tested in trial NCT02947945?
The interventions under investigation include: Reslizumab (DRUG).
Who is sponsoring clinical trial NCT02947945?
This trial is sponsored by National Jewish Health, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.